Pazopanib in Treating Patients With Newly Diagnosed or Locally and/or Regionally Recurrent Breast Cancer That Can Be Removed By Surgery

Inclusion Criteria:

• Diagnosis of invasive adenocarcinoma of the breast by core needle biopsy or limited incisional biopsy
• Tumor size >= 1.0 cm as assessed by physical exam or radiographic exam
• Patients with histologically verified local and/or regional recurrence of invasive breast cancer that is amenable to surgery and meet all eligibility criteria may participate
• No prior chemotherapy or hormonal therapy for this primary breast cancer
• Able to undergo surgical treatment with either lumpectomy or mastectomy
• Eastern Cooperative Oncology Group (ECOG) performance status 0-2
• WBC >= 3,000/mm^3
• Platelet count >= 100,000/mm^3
• Bilirubin within normal institutional limits
• AST and ALT =< 2.5 times upper limit of normal (ULN)
• Creatinine normal OR creatinine clearance >= 60 mL/min
• PT/INR/PTT =< 1.2 times ULN
• Urine protein:creatinine ratio =< 1
• Blood pressure =< 140/90
• Eligibility of patients receiving any medications or substances known to affect or with the potential to affect the activity or pharmacokinetics of GW786034 (pazopanib) will be determined following review by principal investigator
• Women of child-bearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation
• Any concomitant medications that are associated with a risk of QTc prolongation and/or Torsades de Pointes should be discontinued or replaced with drugs that do not carry these risks, if possible; patients who must take medications with a risk or possible risk of Torsades de Pointes should be watched carefully for symptoms of QTc prolongation, such as syncope

Exclusion Criteria:

• Patients with locally advanced breast cancer who are not candidates for surgical resection at time of initial evaluation, including patients with:

  • Tumor of any size with direct extension to chest wall or skin (T4a-c)
  • Inflammatory breast cancer (T4d)
• Patients with evidence of metastatic disease
• Patients may not be receiving any other investigational agents
• Patients with history of allergic reactions attributed to compounds of similar chemical or biologic composition to GW786034 or other agents used in the study

• Patients with any of the following conditions are excluded:

  • Serious or non-healing wound, ulcer, or bone fracture
  • History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 28 days of treatment
  • Any history of cerebrovascular accident (CVA) within the last 6 months
  • Current use of therapeutic warfarin. Note: Low molecular weight heparin and prophylactic low-dose warfarin are permitted; PT/PTT must meet the inclusion criteria (Section 5.1.8)
  • History of myocardial infarction, cardiac arrhythmia, admission for unstable angina, cardiac angioplasty or stenting within the last 12 weeks
  • History of venous thrombosis in last 12 weeks
  • Class III or IV heart failure as defined by the NYHA functional classification system (see Appendix C); a patient who has a history of Class II heart failure and is asymptomatic on treatment may be considered eligible
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or psychiatric illness/social situation that would limit compliance with study requirements
• Baseline QTc >= 480 msecs or other significant ECG abnormalities
• Patients taking certain medications that act through the CYP450 system
• Patients with any condition that impairs their ability to swallow and retain GW786034
• HIV-positive patients
• Patients who are unable or unwilling to sign a written informed consent document